COVID-19 in Chronic Liver Disease and Liver Transplantation
A Clinical Review
Abdul Mohammed, MD,* Neethi Paranji, MD,† Po-Hung Chen, MD,‡ and Bolin Niu, MD†

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has brought challenges to clinicians caring for patients with chronic liver disease. The past 6 months, COVID-19 has led to over 150,000 deaths in the United States and over 660,000 deaths around the world. Mounting evidence suggests that chronic liver diseases can have an adverse effect on the clinical outcomes of patients with COVID-19. We present a comprehensive review of the latest literature on preexisting liver diseases and its interrelationship with COVID-19 infection in cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease, autoimmune hepatitis, and viral hepatitis.

Key Words: cirrhosis, liver transplantation, hepatitis B, nonalcoholic liver disease, hepatocellular carcinoma, autoimmune hepatitis, review, COVID-19, SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus first identified in Wuhan, China. The illness caused by the SARS-CoV-2 virus referred to as coronavirus disease 2019 (COVID-19), has reached pandemic proportions. At the time of compiling this paper, >13 million confirmed cases have been reported globally, of which 3.3 million are in the United States alone. Older populations and comorbidities like diabetes, hypertension, and cardiovascular disease have been associated with an increased mortality rate. It predominantly causes respiratory distress syndrome with gastrointestinal and hepatic manifestations. Mild cases present with fever, dyspnea, fatigue, cough, and diarrhea. Severe cases present with acute hypoxemia, respiratory distress syndrome, and multiple organ dysfunction. SARS-CoV-2 causes comitant liver injury similar to its counterparts, the Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome-associated coronavirus (SARS-CoV). However, the mechanism of injury is poorly understood.

Chronic liver diseases are prevalent worldwide and impose a significant burden on health care services. Their relationship with COVID-19 is not well documented in the literature. The intricate interplay between immune dysfunction in preexisting liver diseases and the immune dysregulation triggered by the SARS-CoV-2 virus needs further evaluation. The prevalence of chronic liver diseases in COVID-19 was reported by Chinese centers to range from 2% to 11%. In the United States, Singh and Khan identified 2780 patients with COVID-19, of which 250 patients (9%) had preexisting liver disease. Mortality of COVID-19 patients with the known liver disease compared with those without was 12% versus 4% [95% confidence interval (CI): 1.5-6.0; relative risk: 3.0, P = 0.001], and it remained high even after propensity score matching for body mass index, hypertension, and diabetes in addition to age, race, and nicotine use. Similarly, in the UK, OpenSAFELY, a secure health analytics platform for electronic health records in the National Health Service (NHS), analyzed data from 17 million patients. It showed that chronic liver disease was a risk factor for in-hospital death from COVID-19 with a hazard ratio of 2.39 (95% CI: 2.06-2.77). Mortality from COVID-19 in patients with chronic liver diseases are often higher than those without liver disease (Table 1).

New reports from several sources are now available that elucidate the epidemiological characteristics of preexisting liver disease in COVID-19 patients. In this article, we will review the effects of COVID-19 in patients with underlying liver disease and summarize guidance from 3 major hepatology societies, the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of Liver (EASL), and the Asian Pacific Association for the Study of Liver (APASL) to present the best approaches for caring for patients with liver diseases as well as those requiring liver transplantation.

MECHANISM OF HEPATIC INJURY FROM SARS-CoV-2 VIRUS

There are 2 major binding sites on the SARS-CoV-2 virus. The spike glycoprotein (S) that is essential for viral entry and the nucleocapsid phosphoprotein (N) that interacts with the RNA. The virus binds to angiotensin-converting enzymes 2 receptors as a portal of entry into the target cell, where it replicates and infects other cells. The expression of these receptors is seen in alveolar type 2 cells and bile duct epithelial cells. The expression in bile duct epithelial cells is much higher than that of liver parenchymal cells. Elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), 1 to 2 times the upper limit of normal, were reported in 14% to 53% of cases. Gamma-glutamyl transpeptidase, a marker of biliary epithelial
cell injury, is elevated in 24% of patients hospitalized with COVID-19.\(^\text{20}\) Higher levels of hepatocellular enzyme elevation have been associated with more severe forms of COVID-19.\(^{6,21}\) In addition, treatments used in the management of COVID-19 can increase liver enzyme levels. Elevated liver enzymes have been reported with remdesivir use. Remdesivir studied for compassionate use in severe COVID-19 patients showed improved outcomes and was even approved by the United States Food and Drug Administration (FDA) for emergency use authorization (EUA) based on the interim analysis. In a study of 61 patients with severe COVID who received compassionate use of remdesivir, 22% of patients showed increased hepatic enzymes. The increase in liver enzymes led to the discontinuation of remdesivir in 2 patients in the study.\(^{22}\) Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is also known to cause severe liver injury.\(^{23}\) A retrospective, observational cohort study reported a decreased need for invasive mechanical ventilation and a lower risk of death in patients with severe pneumonia. In this study, when compared with the standard care group, the tocilizumab group had a significantly higher elevation of ALT.\(^{24}\) Neither remdesivir nor tocilizumab is recommended for use when AST or ALT level is > 5 times the upper limit of normal. Safety and side-effect profiles of treatments in patients with COVID-19 will require future assessment in placebo-controlled trials.

Whether hepatocellular inflammation is a direct consequence of virus-mediated cytokine release and a prognostic marker of disease severity or a direct cytopathogenic response is yet to be determined. In a study of 60 patients from Massachusetts General Hospital, median AST and ALT on admission were 46 and 30 U/L, respectively.\(^{25}\) Ten patients (17%) developed aminotransferases > 5 times the upper limit of normal.\(^{25}\) Elevated levels of AST and ALT were seen in 93% of patients during hospitalization. Since AST is higher than ALT, a nonhepatic injury like myositis can be considered, but correlations with creatinine kinase were weak.\(^{25}\) In short, aminotransferase elevations are common in COVID-19 and appear to mirror disease severity.

Pathologic analysis of tissue obtained from postmortem examination of the liver in patients whose deaths were a direct consequence of COVID-19 showed moderate microvascular steatosis and mild lobular and portal activity. However, viral inclusions were not observed.\(^{26}\)

### Table 1. Mortality in Patients With Coronavirus Disease 2019 and Underlying Chronic Liver Disease Versus Those Without Chronic Liver Disease

| Liver Disease | References | Study Type | Sample Size (n) | Mortality Data |
|---------------|------------|------------|----------------|----------------|
| NAFLD         | Hashemi et al\(^9\) | Multicenter inpatient mortality rate | 363 | 16.4% vs. 13.2% (\(P = 0.54\)) |
| HBV           | Chen et al\(^10\) | Single-center inpatient mortality rate | 123 | 13.3% vs. 2.8% |
| AIH           | Gerussi et al\(^11\) | Multicenter case fatality rate | 10 | 10%*† |
| Cirrhosis     | Iavarone et al\(^12\) | Multicenter retrospective inpatient case fatality rate | 50 | 34% (95% CI: 23%-49%) |
| LT            | Fraser et al\(^14\) | Multicenter matched cohort inpatient case fatality | 165 | 30% vs. 13% (\(P = 0.03\)) |

*The death event occurred in the frailest patient included in the cohort who already had decompensated cirrhosis, which is associated with significant morbidity and mortality.
†These are not comparative studies.
AIH indicates autoimmune hepatitis; CI, confidence interval; HBV, hepatitis B virus; LT, liver transplant; NAFLD, nonalcoholic fatty liver disease.
| Disease | AASLD | EASL | APASL |
|---------|-------|------|-------|
| NAFLD   | No specific recommendations | Continue treatment of hypertension with ACE inhibitors or ARBs. | No specific recommendations |
| HBV     | Continue treatment for chronic HBV if already receiving treatment. | Continue treatment for chronic HBV if already receiving treatment. | Continue treatment for chronic HBV if already receiving treatment. |
|         | In patients with COVID-19, defer initiation of treatment for HBV until recovery. | In patients with COVID-19, defer initiation of treatment for HBV until recovery. | In patients with COVID-19, defer initiation of treatment for HBV until recovery. |
|         | In patients with COVID-19, initiate therapy if there is clinical suspicion of HBV flare or when initiating immunosuppressive therapy. | | In patients with COVID-19, initiate therapy if there is clinical suspicion of HBV flare or when initiating immunosuppressive therapy. |
| AIH     | In AIH patients on immunosuppression without COVID-19 infection do not decrease immunosuppression. | In AIH patients on immunosuppression without COVID-19 infection do not decrease immunosuppression. | In AIH patients continue immunosuppressive therapy with mild COVID-19 infection. |
|         | In AIH patients on immunosuppression with COVID-19, consider lowering overall immunosuppression, particularly antimitabolites | In COVID-19 patients consider budesonide to minimize systemic glucocorticoid exposure for management of acute flare of AIH. | Do not discontinue corticosteroids in AIH patients with severe COVID-19 infection and use stress doses as needed. |
| HCC     | Continue surveillance for HCC in patients at risk, although a delay of 2 mo is reasonable. | If resources are limited prioritize high risk patients in conjunction with the use of published HCC risk stratification score. | Consider postponing of elective transplant, resection surgery or radiotherapy for newly diagnosed HCC patients. |
|         | In patients positive for SARS-CoV-2 infection avoid HCC surveillance. | | Consider initiation of ablative procedures, transcatheter arterial chemoembolization, kinase inhibitors or immunotherapy. |
|         | Consider virtual visits to discuss diagnosis and management of HCC. | Multidisciplinary management of HCC should continue remotely. | Withhold immunosuppressive therapy if HCC patients are infected with SARS-CoV-2. |
| Cirrhosis| Maintain a low threshold to test patients with cirrhosis for SARS-CoV-2. | For patients infected with SARS-CoV-2, follow guideline directed therapy to prevent hepatic decompensation. | No specific recommendations. |
|         | Prioritize in-person evaluation of patients with decompensated cirrhosis. | Prioritize in-person evaluation of patients with decompensated cirrhosis. | |
| LT      | Prioritize LT for patients with acute liver failure, ACLF, high MELD score and HCC at upper limits of the Milan criteria. | Prioritize LT for patients with acute liver failure, ACLF, high MELD score and HCC at upper limits of the Milan criteria. | Prioritize LT for patients with acute liver failure, ACLF, high MELD score and HCC at upper limits of the Milan criteria. |
|         | Before organ procurement evaluate donor for COVID-19 infection with a nasopharyngeal swab and chest CT. | Before organ procurement evaluate donor for COVID-19 infection with a nasopharyngeal swab and chest CT. | Before organ procurement evaluate donor for COVID-19 infection with a nasopharyngeal swab and chest CT. |
|         | Avoid organ transplantation from donors positive for SARS-CoV-2 infection. | Avoid organ transplantation from donors positive for SARS-CoV-2 infection. | Avoid organ transplantation from donors positive for SARS-CoV-2 infection. |
|         | In SARS-CoV-2-positive transplant candidates consider transplantation at least 14-21 d after symptom resolution and 1 or 2 negative SARS-CoV-2 diagnostic tests. | | Assess recipients for COVID-19 infection symptoms and exposure. |
| Post-LT | In posttransplant patients without COVID-19, do not decrease immunosuppression. | In posttransplant patients without COVID-19, do not decrease immunosuppression. | In posttransplant patients with COVID-19, do not decrease immunosuppression. |
|         | In posttransplant patients with COVID-19, consider lowering overall immunosuppression, particularly antimitabolite therapy. | Closely monitor drug levels of calcineurin inhibitors and mechanistic target of rapamycin inhibitors when they are administered together with drugs for COVID-19. | Immunosuppression should be reduced in patients with lymphopenia, fever, or worsening pneumonia. |
|         | | Consider early admission for all LT recipients who develop COVID-19. | |

AASLD indicates American Association for the Study of Liver Disease; ACE, angiotensin-converting enzyme; ACLF, acute-on-chronic liver failure; AIH, autoimmune hepatitis; APASL, Asian Pacific Association for the Study of Liver; ARB, angiotensin receptor blocker; COVID-19, coronavirus disease 2019; CT, computed tomography; EASL, The European Association for the Study of Liver; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LT, liver transplant; MELD, Model for End-stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
The overall mortality was higher in patients with liver injury than those without (28.57% vs. 3.30%, \( P = 0.004 \)). In a small retrospective study, Chen and colleagues showed that COVID-19 patients with preexisting HBV disease had a more severe disease course (46.7% vs. 24.1%) and a higher mortality rate (13.3% vs. 2.8%) when compared with patients without HBV coinfection. However, larger studies are needed to assess the impact of coinfection with HBV and SARS-CoV-2.

Since the first cases of COVID-19 were reported in December 2019, the treatment of COVID-19 has evolved dramatically. We now recognize the rapid clinical deterioration of patients from cytokine-mediated immune damage. Immunosuppressants and steroids are now at the forefront of the management of COVID-19. Reactivation of HBV in COVID-19 is a concern when using immunosuppressive therapy. In a recent study of HBV patients with only positive HBV core antibody receiving corticosteroids, the risk of a hepatitis flare started to increase in those receiving corticosteroids at peak daily doses of 20 to 40 mg (adjusted hazard ratio: 2.19, \( P = 0.048 \)) or > 40 mg (adjusted hazard ratio: 2.11, \( P = 0.015 \)) prednisolone equivalents for < 7 days. Consensus statements from major societies agree that antiviral treatment of HBV during immunosuppressive drug therapy is indicated in those with HBV surface antigen positivity or HBV core antibody positivity, depending on the level of immunosuppression.

A prospective observational study reported an increased risk of HBV reactivation in patients with rheumatoid arthritis and chronic HBV infection receiving tocilizumab. However, reactivation rates of chronic HBV infection in COVID-19 patients receiving tocilizumab are unknown. It remains unclear if antiviral prophylaxis should be initiated in these cases.

The AASLD, EASL, and APASL do not recommend routinely initiating treatment of hepatitis B in patients with COVID-19 unless there is clinical suspicion of a hepatitis flare.

AUTOMMUNE HEPATITIS (AIH)

The impact of COVID-19 infection on AIH is unclear. It has been suggested that an immunosuppressive state can predispose to infection with the SARS-CoV-2 virus. However, a study of AIH patients under immunosuppression in Northern Italy reported a similar prevalence of COVID-19 infection in the study group as in the general population. A similar study in Belgium did not find an increased susceptibility to contract COVID-19 patients in AIH patients on immunosuppression. A retrospective analysis reported a similar disease course in AIH patients on immunosuppression when compared with patients not on immunosuppression. Overall, AIH patients on immunosuppression did not have worse outcomes.

The EASL, AASLD, and APASL caution against withdrawing immunosuppression in AIH patients with COVID-19 as it may lead to hepatitis flares. In AIH patients with COVID-19 infection, the recommendation is to lower immunosuppression while maintaining a level of corticosteroids sufficient to prevent adrenal insufficiency.

CIRRHOSIS

Cirrhosis predisposes to higher mortality in those affected by COVID-19. A retrospective Italian study of 50 patients with cirrhosis and concomitant COVID-19 infection reported a high 30-day mortality of 34%. Outcomes were worse in patients with higher Model for End-Stage Liver Disease (MELD) scores. While respiratory failure was reported as the most common cause of death in these patients, it is important to note that decompensated cirrhosis can predispose to pulmonary complications. We need more studies to determine the correlation between pulmonary complications of decompensated cirrhosis and respiratory distress related to COVID-19. Another cohort study of 250 patients with prior diagnoses of chronic liver diseases reported a higher mortality risk in patients with cirrhosis (relative risk: 4.6; 95% CI: 2.6-8.3). Preliminary analysis of data from 2 international self-reporting registries, COVID-Hepl.net and COVIDCirrhosis.org, reported high mortality in cirrhotic patients with COVID-19. Mortality is strongly correlated with the Child-Turcotte-Pugh (CTP) class with a mortality of 23.9% in CTP-A, 43.3% in CTP-B, and 63.0% in CTP-C. Hepatic decompensation in compensated cirrhosis patients strongly correlated with the risk of death when compared with patients without decompensation (63.2% vs. 26.2%).

Furthermore, an international study comprised of cohorts from 13 Asian countries showed that acute-onchronic liver failure or acute decompensation occurred in 20% of cirrhotic patients with COVID-19. This is an important observation as it indicates that patients with cirrhosis are predisposed to severe hepatotoxic injury by the SARS-CoV-2 virus. SARS-CoV-2 selectively binds to angiotensin-converting enzymes 2 receptors on the bile duct epithelial cells that play important roles in liver regeneration and immune response. The liver is a crucial component of the reticuloendothelial system and is responsible for innate immunity. Cirrhosis impairs this homeostatic response conferred by the reticuloendothelial system of the liver. As the disease progresses, it switches from a proinflammatory to an immune-deficient state. The cytokine-mediated immune response in a patient with a diminished liver reserve may lead to hepatic decompensation. Consequently, when patients with a diagnosis of cirrhosis present with acute elevation of liver enzymes, in addition to excluding infectious etiologies like hepatitis and drug-induced liver injury, testing for COVID-19 should be considered.

HEPATOCELLULAR CARCINOMA (HCC) SCREENING AND MANAGEMENT

HCC screening has taken a back seat because of social distancing practices and staffing shortages. Since the tumor doubling time is 4 to 8 months and current guidelines recommend screening every 6 months, in patients at lower risk for developing HCC, a 2-month delay in ultrasound surveillance has been suggested by the AASLD. In patients with a high risk of developing HCC, 6-month interval screening should be continued. The EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) suggest deferring HCC surveillance in patients testing positive for COVID-19 until recovery or negative reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 are achieved. Nosocomial spread of infection is a cause of concern for patients presenting for the management of HCC. The objective is to minimize aerosolization procedures, conserve utilization of anesthesia resources, reduce the length of hospital stay, and provide adequate follow-up.
Screening questionnaires can be used for identifying patients with active symptoms and for identifying patients with close contact with patients diagnosed with COVID-19. Pre-procedural workup including RT-PCR for SARS-CoV-2 can be performed in the outpatient setting.60

There is uncertainty regarding whether HCC treatment should be initiated in COVID-19 patients with newly diagnosed HCC. Delaying treatment can lead to the progression of HCC with detrimental outcomes, but surgical resection may increase the risk of transmission to health care workers. In addition, tyrosine kinase inhibitors or checkpoint inhibitors may worsen COVID-19 by worsening a cytokine storm. AASL recommendation is for HCC treatment to proceed17; whereas, EASL recommends postponing locoregional therapies if possible and for checkpoint inhibitors to be temporarily withheld in patients with COVID-19.59 The APASL recommends postponing elective transplant and resection for HCC and proceeding with locoregional therapy. APASL suggests tyrosine kinase inhibitor and immunotherapy can be started but given at a less frequent schedule of every 4 to 6 weeks.17

LT
In LT patients, the risk of infection with SARS-CoV-2 and the severity of outcomes remain unclear.61 The University of Washington maintains a regularly updated registry of solid organ transplant (SOT) recipients with COVID-19. A preliminary analysis of data from this registry was reviewed at a webinar hosted by the AASLD. It reported that the risk of contracting SARS-CoV-2 in SOT recipients is comparable to the general population, with advanced age and comorbidities such as diabetes being risk factors that showed a disproportionate rate of infection. Although the 28-day all-cause mortality in LT recipients is reported >20%, it is similar to the inpatient case fatality rate in the general population as reported by other registries.62,63 COVID-19 and SARS-CoV-2 patients are voluntary international registries that collect relevant data on COVID-19 patients and underlying chronic liver disease and LT. Of the 159 LT patients described in their latest report, 81% were hospitalized, 30% required intensive care unit (ICU) care, and 19% died.54,65 Preliminary data from the European Liver and Intestine Transplant Association (ELITA) registry indicates that older LT recipients have higher mortality.66 In a systematic review of SOT patients with COVID-19, 16 cases of LT were described. The fatality rate among LT recipients was 37.5%.67,68

The Centers for Medicare and Medicaid Services (CMS), in an effort to prioritize health care resources, have provided a tiered framework to classify nonemergent, elective medical services. They have designated transplant surgery as Tier 3b or nonessential, low-priority medical service. Yet, transplant centers are faced with the difficult task of devising region-specific models of care to combat the unique challenges presented to them.59,60 Because of COVID-19-related limitations, there has been a decrease in organ procurement.71 Before resuming transplant services, health care facilities are encouraged to consider the availability of resources, staffing issues, and nosocomial spread of infection. Telemedicine visits have become increasingly popular in evaluating LT recipients, who are likely to benefit from immediate transplant listing since patients are being discouraged from attending in-office visits and undergoing any invasive or noninvasive testing.57 The Organ Procurement and Transplantation Network (OPTN) has temporarily relaxed the frequency of updating MELD scores for listed patients.72

As transplant activity resumes amidst the pandemic, all 3 liver societies recommend limiting LT to patients with high MELD scores, the risk for decompensation, or HCC progression.17,57,59 Potential donors are assessed for exposure history with known or suspected COVID-19 patients and travel to an affected region. All donors are screened with an RT-PCR assay of the nasopharyngeal swab for the SARS-CoV-2 virus and a screening CT scan of the chest.73 Ai et al74 reported a sensitivity of 97% for chest CT imaging in detecting COVID-19, compared with a lower sensitivity of RT-PCR testing at 71%. Symptomatic donors who are positive by RT-PCR or CT chest are rejected.73 AASL recommends against LT in patients with COVID-19. However, LT can proceed 21 days after symptom resolution and negative diagnostic tests in recipients.57

POSTTRANSPLANT CARE AND IMMUNOSUPPRESSION

The postoperative period immediately following the transplant requires cardiovascular support and access to critical care units. To ensure optimum transplant success rate and to prevent nosocomial transmission, the Birmingham Liver Unit in the UK established a SARS-CoV-2-free pathway, which meant a dedicated ICU and ward for posttransplant care.75 Perioperative transplant care should be encouraged where feasible through telehealth visits. At these encounters, patients should be routinely screened for symptoms related to SARS-CoV-2 like fevers, dyspnea, cough, diarrhea, and altered sense of taste or smell. Symptomatic patients should be encouraged to present to the hospital for further evaluation.76

In LT recipients without COVID-19, all 3 liver associations recommend against reducing immunosuppression.17,57,59 There has been no data to suggest that posttransplant immunosuppression is a risk factor in COVID-19 severity. In contrast, reducing immunosuppression may increase the risk of graft rejection. AASLD advocates for telemedicine in posttransplant care as well as telework options for LT recipients.57 In LT recipients with COVID-19, AASLD recommends lowering the overall level of immunosuppression, particularly antimetabolite dosages, while maintaining the dosage of calcineurin inhibitors (CNIs) the same.57 This is based on the general principles for managing infections in transplant recipients.

Cytokine release from activation of the host’s immune system is the primary driver of tissue damage in COVID-19.77 Consequently, immunosuppression can potentially curb this response. The RECOVERY trial’s preliminary, non-peer-reviewed report stated the effectiveness of short-term dexamethasone in reducing 28-day mortality in COVID-19 patients on the ventilator support by one third and those requiring noninvasive oxygen support without invasive ventilation by one fifth.31 At the same time, it is important to note that inflammatory bowel disease patients on systemic corticosteroid therapy and COVID-19 had markedly worse outcomes in the form of increased admission to the ICU, mechanical ventilation, and death (adjusted OR: 6.87; 95% CI: 2.3-20.5).65 In vitro studies show that coronavirus replication, which is dependent on immunophilin pathways, is inhibited by tacrolimus.66 Similarly, limited data exist on the antiviral effects of cyclosporine. In kidney transplant patients infected with SARS-CoV-2 virus, the cyclosporine only group reported fewer deaths (13%) when compared with a group that minimized immunosuppression (50%).67
Immunosuppressive therapy also has the potential to complicate the treatment of SARS-CoV-2 in SOT recipients. The drug-drug interactions between dexamethasone and CNIs and the liver toxicity associated with remdesivir and tocilizumab are well documented and may preclude their use in the treatment of COVID-19 in LT recipients.²⁴,⁶⁸

**IMPACT OF THE MANAGEMENT OF COVID-19 ON UNDERLYING LIVER DISEASE**

The therapeutic options for treatment of COVID-19 are continuously evolving. There are currently no medications approved for the treatment of COVID-19. Remdesivir received EUA from the FDA when an interim analysis showed improved recovery times.⁷⁸ Due to aminotransferase elevations, 2.5% of patients in the 5-day group and 3.6% of patients in the 10-day group discontinued treatment.⁷⁹ In the largest randomized controlled trial conducted, investigators did not report a significant difference between aminotransferase elevations in patients taking remdesivir compared with placebo.⁷⁸

Patients with aminotransferase elevations >5 times the upper limit of normal were excluded from the study. No data is available on the effect of remdesivir on underlying liver disease in COVID-19 patients. In fact, cirrhosis patients were excluded from the multicenter trial discussed above.

Monoclonal interleukin-6 receptor antagonists counter the cytokine-mediated injury in severe COVID-19. Tocilizumab has a significant hepatotoxic side-effect profile, and regular monitoring of liver biochemistries should be performed. A prospective study evaluated the risk of hepatitis B reactivation in rheumatoid arthritis patients on disease-modifying agents receiving tocilizumab. Among 63 rheumatoid arthritis patients with chronic hepatitis B, 3 patients developed reactivation. None of the patients in the study received any antiviral prophylaxis. All 3 patients were asymptomatic and improved with antiviral therapy.⁴⁷

In addition, lopinavir-ritonavir has been studied in clinical trials for the management of COVID-19. Ritonavir inhibits CYP3A4, which regulates the metabolism of CNIs used in LT patients. Ritonavir increases tacrolimus concentration in blood and requires dosage reduction. When compared with standard of care in severe COVID-19 patients, lopinavir-ritonavir did not show any clinical benefit. In some patients treatment had to be discontinued because of adverse events.⁴⁰

Last, COVID-19 and cirrhosis both alter the coagulation pathway. It is unclear if the presence of both cirrhosis and COVID-19 increases the risk of thromboembolic events when compared with the risk of thromboembolism imposed by either condition alone. It remains to be determined if COVID-19 patients with cirrhosis benefit from therapeutic anticoagulation. A multicenter retrospective study did not observe any major hemorrhagic complications when thromboprophylaxis with heparin was given to patients with cirrhosis and confirmed SARS-CoV-2 infection.¹²

**CONCLUSIONS**

COVID-19 patients with the preexisting liver disease face a higher risk of decompensation and mortality. We presented the most up-to-date literature on preexisting liver disease and its interaction with COVID-19. Our article also focused on changes in current practices of LT. Epidemiological modeling predicts more waves of infection after the first wave unless a vaccine or effective treatment modality becomes available. We should draw on our current experiences and develop mitigation strategies to combat the next waves more effectively.

**REFERENCES**

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
2. Johns Hopkins Coronavirus Resource Center. COVID-19 map; 2020. Available at: https://coronavirus.jhu.edu/map.html. Accessed July 14, 2020.
3. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
5. Kukla M, Skonieczna-Zydecka K, Kotfis K, et al. COVID-19, MERS and SARS with concomitant liver injury-systematic review of the existing literature. J Clin Med. 2020;9:1420.
6. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428–430.
7. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768.e1–771.e3.
8. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.
9. Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. Liver Int. 2020;40:2515–2521.
10. Chen X, Jiang Q, Ma Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus co-infection. Virol Sin. 2020. doi: 10.1007/s12250-020-00276-5.
11. Gerussi A, Rigamonti C, Elia C, et al. Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun. 2020;4:1257–1262.
12. Iavarone M, D’Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–1071.
13. Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2020. doi: 10.1136/gutjnl-2020-322118.
14. Fraser J, Mousley J, Testro A, et al. Clinical presentation, treatment, and mortality rate in liver transplant recipients with coronavirus disease 2019: a systematic review and quantitative analysis. Transplant Proc. 2020;52:2676–2683.
15. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287–304.
16. Boettler T, Marjot T, Newsome PN, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2:100169.
17. APASL Covid-19 Task Force, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415–428.
18. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220.
19. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv; 2020.

20. Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73:566–574.

21. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.

22. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382:2327–2336.

23. Gatti M, Fusirolli M, Caraceni P, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2020. doi: 10.1111/bcp.14459.

24. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–e484.

25. Bloom PP, Meyerowitz EA, Reins Z, et al. Liver Biochemistries in hospitalized patients with COVID-19. Hepatology. 2020. [Epub ahead of print].

26. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:411–417.

27. Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 29 patients with COVID-19 in Wuhan, China: a retrospective cohort study. J Clin Invest. 2020;135:1054–1062.

28. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020;71:896–897.

29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.

30. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020;107:154217.

31. Portincasa P, Krawczyk M, Smyk W, et al. COVID-19 and nonalcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338.

32. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2020;35:221–235.

33. Qian ZP, Mei X, Zhang YY, et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area. Zhonghua Gan Zang Bing Za Zhi. 2020;28:229–233.

34. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73:451–453.

35. Zheng KI, Gao F, Wang X-B, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS-CoV-2 infection: The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020:14:690–700.

36. Banales JM, Huerta RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16:269–281.

37. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: interrelated features and clinical relevance. J Hepatol. 2014;61:1385–1396.

38. Bonnel AR, Bunchornvavilkul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:727–738.

39. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287–304.

40. Rosenblatt R, Verna EC. COVID-19: management of decompensated cirrhosis and liver transplant recipients. Clin Liver Dis (Hoboken). 2020:15:200–203.

41. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ECLF Management of Patients with Liver Disease during COVID-19 dashboard. 2020. Available at: https://ilca-online.org/management-of-hcc-during-covid-19-ilca-guidance/.

42. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762–768.

43. recovery Collaborative Group, Horby P, Lim WS, Emerson JR, et al. Dexamethasone in hospitalized patients with COVID-19—preliminary report. N Engl J Med. 2020. [Epub ahead of print].

44. Varona Pérez J, Rodríguez Chinea JM. Risk of hepatitis B reactivation associated with treatment against SARS-CoV-2 (COVID-19) with corticosteroids. Rev Clin Esp (Barc). 2020;220:535–536.

45. Wang GL-H, Wong YW-S, Yuen BW-Y, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2020;72:57–66.

46. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–219; quiz e16–e17.

47. Chen J-F, Mo Y-Q, Jing J, et al. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20:859–869.

48. Reddy KR. SARS-CoV-2 and the Liver: Considerations in the Liver. J Hepatol Dis (Hoboken). 2020;15:191–194.

49. Di Giorgio A, Nicastro E, Speziani C, et al. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol. 2020;73:702–705.

50. Verhelst X, Somers N, Geerts A, et al. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J Hepatol. 2020. [Epub ahead of print].

51. Machicado VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59:1627–1637.

52. Karcez M, Bankey B, Schwaiberger D, et al. Acute respiratory failure complicating advanced liver disease. Semin Respir Crit Care Med. 2012;33:96–110.

53. Eserin SK, Choudhury R, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS-CoV2 infection: The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14:690–700.

54. Ceballos G, Francino JM, Berenguer E, et al. COVID-19 and the Liver: Considerations in the Liver. J Hepatol Dis (Hoboken). 2020;15:191–194.

55. Kwok-Ting Lee, Wai-Man Chan, et al. COVID-19 in patients with metabolic dysfunction: crosstalk with metabolism. Eur J Gastroenterol Hepatol. 2020;32:229–233.

56. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: interrelated features and clinical relevance. J Hepatol. 2014;61:1385–1396.

57. Bonnel AR, Bunchornvavilkul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:727–738.

58. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287–304.

59. Rosenblatt R, Verna EC. COVID-19: management of decompensated cirrhosis and liver transplant recipients. Clin Liver Dis (Hoboken). 2020:15:200–203.

60. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ECLF Management of Patients with Liver Disease during COVID-19 dashboard. 2020. Available at: https://ilca-online.org/management-of-hcc-during-covid-19-ilca-guidance/.

61. D’Agostino LA. Coronavirus and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26:832–834.

62. UW Medicine: UW virology COVID-19 dashboard; 2020. Available at: https://deerpt.washington.edu/labmed/covid19/. Accessed July 11, 2020.

63. American Association for the Study of Liver Disease (AASLD); AASLD-AST COVID-19 and the liver: chronic liver disease and...
64. Moon AM, Baritt AS, Dhanasekaran R, et al. SECURE Cirrhosis Registry. Available at: https://covidcirrhosis.web.unc.edu/. Accessed July 13, 2020.

65. Marjot T, Webb G, Cargill T, et al. COVID-Hep registry. Available at: www.covid-hep.net/. Accessed July 13, 2020.

66. Belli LS, Duvoux C, Karam V, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. *Lancet Gastroenterol Hepatol*. 2020;5:724–725.

67. Nacif LS, Zanini LY, Waisberg DR, et al. COVID-19 in solid organ transplantation patients: a systematic review. *Clinics (Sao Paulo)*. 2020;75:e1983.

68. Centers for Medicare and Medicaid Services (CMS). CMS Adult elective surgery and procedures recommendations. 2020.

69. Agopian V, Verna E, Goldberg D. Changes in liver transplant center practice in response to COVID-19: unmasking dramatic center-level variability. *Liver Transpl*. 2020;26:1052–1055.

70. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. *Am J Transplant*. 2020;20:1809–1818.

71. Loupy A, Aubert O, Reese PP, et al. Organ procurement and transplantation during the COVID-19 pandemic. *Lancet*. 2020;395: e95–e96.

72. United Network for Organ Sharing (UNOS). Actions address transplant candidate data reporting, candidate inactivation related to COVID-19; 2020. Available at: https://unos.org/news/transplant-candidate-data-reporting-candidate-inactivation-related-to-covid-19/. Accessed July 13, 2020.

73. Galvan NTN, Moreno NF, Garza JE, et al. Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic. *Am J Transplant*. 2020;20:3113–3122.

74. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology*. 2020;296:E32–E40.

75. Lembach H, Hann A, McKay SC, et al. Resuming liver transplantation amid the COVID-19 pandemic. *Lancet Gastroenterol Hepatol*. 2020;5:725–726.

76. El Kassas M, Alboradie M, Al Balakosy A, et al. Liver transplantation in the era of COVID-19. *Arab J Gastroenterol*. 2020;21:69–75.

77. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. *Clin Gastroenterol Hepatol*. 2020;18:1561–1566.

78. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—preliminary report. *N Engl J Med*. 2020. [Epub ahead of print].

79. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. *N Engl J Med*. 2020;383:1827–1837.

80. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. *N Engl J Med*. 2020;382:1787–1799.